UBS AM’s MoonLake Immunotherapeutics MLTX Stock Holding History

UBS AM’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.38M	Buy	+74,162	New	+$1.23M	﹤0.01%	2201
2025 Q3	–	Sell	-19,164	Closed	-$905K	–	2473
2025 Q2	$905K	Sell	19,164 -24,640	-56%	-$1M	﹤0.01%	2409
2025 Q1	$1.71M	Buy	43,804 +1,568	+4%	+$67.6K	﹤0.01%	2068
2024 Q4	$2.29M	Buy	42,236 +6,422	+18%	+$328K	﹤0.01%	1971
2024 Q3	$1.81M	Buy	35,814 +17,580	+96%	+$824K	﹤0.01%	2086
2024 Q2	$802K	Buy	18,234 +3,003	+20%	+$127K	﹤0.01%	2471
2024 Q1	$765K	Hold	15,231	–	–	﹤0.01%	2145
2023 Q4	$920K	Buy	15,231 +53	+0.3%	+$2.73K	﹤0.01%	2070
2023 Q3	$865K	Buy	+15,178	New	+$838K	﹤0.01%	2030

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS AM's MLTX Position: Q1 2026 in Review

UBS AM opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 74,162 shares worth $1.38M. The stake represents ﹤0.01% of the portfolio and ranks #2201 among its holdings. This is a return to the name: UBS AM previously reported a position in MLTX as recently as Q2 2025.

UBS AM first reported a position in MLTX in Q3 2023 and has held it in 9 quarters since. The position peaked at $2.29M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

UBS AM held 74,162 shares of MoonLake Immunotherapeutics worth $1.38M as of Q1 2026.
MoonLake Immunotherapeutics was a new UBS AM position in Q1 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2201 holding.
UBS AM first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 9 quarters since.
UBS AM's MoonLake Immunotherapeutics position peaked at $2.29M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.